User login
Key clinical point: Disease activity-guided dose optimization (DAGDO) of tumor necrosis factor inhibitor (TNFi) showed no negative effect on disease activity in patients with psoriatic arthritis (PsA).
Major finding: Compared with the full-dose continuation period, the mean disease activity score in 28-joint count C-reactive protein was not significantly different for DAGDO (0.06; P = .44) and stable dose after DAGDO (0.03; P = .72) periods. Moreover, the rate ratio of infections was not different in DAGDO (0.76; P = .57) and stable dose after DAGDO (0.77; P = .60) periods compared to the full-dose continuation period.
Study details: Findings are from 2 controlled, parallel, retrospective cohorts including 153 patients with PsA and 171 patients with axial spondyloarthritis who were doing well taking TNFi and were eligible for DAGDO.
Disclosures: This study did not report any source of funding. Dr. den Broeder A declared receiving consultancy, honoraria, congress invitations, and research grants from various sources.
Source: Michielsens CAJ et al. Rheumatology. 2021 Oct 2. doi: 10.1093/rheumatology/keab741.
Key clinical point: Disease activity-guided dose optimization (DAGDO) of tumor necrosis factor inhibitor (TNFi) showed no negative effect on disease activity in patients with psoriatic arthritis (PsA).
Major finding: Compared with the full-dose continuation period, the mean disease activity score in 28-joint count C-reactive protein was not significantly different for DAGDO (0.06; P = .44) and stable dose after DAGDO (0.03; P = .72) periods. Moreover, the rate ratio of infections was not different in DAGDO (0.76; P = .57) and stable dose after DAGDO (0.77; P = .60) periods compared to the full-dose continuation period.
Study details: Findings are from 2 controlled, parallel, retrospective cohorts including 153 patients with PsA and 171 patients with axial spondyloarthritis who were doing well taking TNFi and were eligible for DAGDO.
Disclosures: This study did not report any source of funding. Dr. den Broeder A declared receiving consultancy, honoraria, congress invitations, and research grants from various sources.
Source: Michielsens CAJ et al. Rheumatology. 2021 Oct 2. doi: 10.1093/rheumatology/keab741.
Key clinical point: Disease activity-guided dose optimization (DAGDO) of tumor necrosis factor inhibitor (TNFi) showed no negative effect on disease activity in patients with psoriatic arthritis (PsA).
Major finding: Compared with the full-dose continuation period, the mean disease activity score in 28-joint count C-reactive protein was not significantly different for DAGDO (0.06; P = .44) and stable dose after DAGDO (0.03; P = .72) periods. Moreover, the rate ratio of infections was not different in DAGDO (0.76; P = .57) and stable dose after DAGDO (0.77; P = .60) periods compared to the full-dose continuation period.
Study details: Findings are from 2 controlled, parallel, retrospective cohorts including 153 patients with PsA and 171 patients with axial spondyloarthritis who were doing well taking TNFi and were eligible for DAGDO.
Disclosures: This study did not report any source of funding. Dr. den Broeder A declared receiving consultancy, honoraria, congress invitations, and research grants from various sources.
Source: Michielsens CAJ et al. Rheumatology. 2021 Oct 2. doi: 10.1093/rheumatology/keab741.